A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

INCB024360 is an oral inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO), which catalyzes the degradation of tryptophan to kynurenine. Preclinical data suggest that IDO1 inhibition by INCB024360 will increase T cell proliferation, and decrease T regulatory cells and myeloid derived suppressor...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2019-03, Vol.19 (3), p.157-161
Hauptverfasser:	Komrokji, Rami S., Wei, Sheng, Mailloux, Adam W., Zhang, Ling, Padron, Eric, Sallman, David, Lancet, Jeffrey E., Tinsley, Sara, Nardelli, Lisa A., Pinilla-Ibarz, Javier, Epling-Burnette, Pearlie K., List, Alan F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Hypomethyalting agents failure Immune Innate immunity MDSC T reg cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!